Ben Novak

Ben Novak is a senior director at Beacon Therapeutics, overseeing the surgical training and support team for innovative ocular gene therapies, with a focus on developing a first-in-class program for commercialization since August 2023. Prior to this role, Novak served as associate director at Novartis Gene Therapies, facilitating the acquisition of Gyroscope. During tenure at Gyroscope Therapeutics, Novak excelled as a surgical technical expert, providing training and support for ophthalmology trials involving gene therapies. Novak's extensive experience in the ophthalmology sector includes various senior product management positions at Genentech, where responsibilities encompassed product development, brand strategy, and market analysis for multiple ophthalmic products. Earlier career experiences include marketing management roles at Novartis, project management at HealthIQ, and sales and marketing in respiratory fields at GlaxoSmithKline and GlaxoWellcome. Educational background includes an MBA from the University of Adelaide and a BS in Chemistry from UCLA.